Opthea Presents Additional Positive Data from OPT-302 Phase 1/2a Wet AMD Trial at ASRS Meeting
August 15, 2017 05:30 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Aug 15, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced further positive results...
Opthea to Present at the American Society of Retinal Specialists Annual Meeting and the Ophthalmology Innovation Summit
August 09, 2017 05:30 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Aug 9, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, announced today that the Company will...
Opthea to Present at the Wedbush PacGrow Healthcare Conference
August 07, 2017 05:30 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Aug 7, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, today announced that the Company will be...
Opthea Receives Notice of Allowance for Key Patent Covering OPT-302 in the United States
July 06, 2017 05:30 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Jul 6, 2017) - Opthea Limited (ASX: OPT)
Composition of Matter and Method of Use claims
Patent coverage for OPT-302...
Opthea Completes A$45 Million Capital Raising
April 28, 2017 05:30 ET
|
Opthea Limited
MELBOURNE, AUSTRALIA--(Marketwired - Apr 28, 2017) - Opthea Limited (ASX: OPT) ("Opthea"), a developer of novel biologic therapies for the treatment of eye diseases, announced today the completion...
Opthea Reports Positive Phase 1/2A Clinical Results for OPT-302 in wet AMD
April 02, 2017 20:16 ET
|
Opthea Limited
MELBOURNE, AUSTRALIA--(Marketwired - Apr 2, 2017) - Opthea Limited (ASX: OPT)
Live webcast with presentation slides:
https://www.webcaster4.com/Webcast/Page/1668/20456 or
...
Opthea Conference Call/Webcast -- Update on OPT-302 Phase 1/2A Wet AMD Clinical Trial
March 31, 2017 05:40 ET
|
Opthea Limited
MELBOURNE, AUSTRALIA--(Marketwired - Mar 31, 2017) - Opthea Limited (ASX : OPT), Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, will host a conference...
Opthea Receives Positive Feedback from European Regulatory Agencies for the OPT-302 Clinical Program in wet AMD
March 20, 2017 05:30 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Mar 20, 2017) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, has concluded positive European scientific...
Opthea Completes FDA Meeting to Inform OPT-302 wet AMD Clinical Program
March 08, 2017 16:44 ET
|
Opthea
MELBOURNE, AUSTRALIA--(Marketwired - Mar 8, 2017) - Opthea Limited (ASX: OPT) -- Opthea Limited, a developer of novel biologic therapies for the treatment of eye diseases, has completed a Type C...
Opthea Completes Patient Enrolment in Phase 1/2A wet AMD Clinical Trial
November 21, 2016 05:30 ET
|
Opthea Limited
MELBOURNE, AUSTRALIA--(Marketwired - Nov 21, 2016) - Opthea Limited (ASX: OPT), a developer of novel biologic therapies for the treatment of eye diseases, has completed patient enrolment in the...